2023-507066-91-00已完成1 期
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Merck Healthcare KGaA
Scientific
Merck Healthcare KGaA
研究点 (1)
Loading locations...
相似试验
已完成
4 期
An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to European sourced Valtrex® Tablets in normal, healthy subjects under fasting conditions.2024-516184-87-00Dermax, Dermax30
已完成
4 期
An open label, randomized, three-period, three-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to Valtrex® extemporaneous suspension in normal, healthy subjects under fasting conditions and to investigate the effect of food on the bioavailability of Valacyclovir Oral Suspension.2023-504760-42-00Dermax30
已完成
4 期
An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparing Alverine citrate/Simeticone 60 mg/300 mg soft capsules to Meteospasmyl 60 mg/300 mg soft capsules in healthy male and female subjects under fed conditions.2024-516942-21-00Zaklady Farmaceutyczne Polpharma S.A.36
进行中（未招募）
1 期
A study investigating the safety, absorption and elimination of 2 formulations of Bosutinib, a drug in the treatment of chronic myeloid leukemia.EUCTR2020-002782-34-NLPfizer Inc.66
已完成
不适用
A phase 1, open-label, randomized, 2-period, 2-sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants under fed conditiochronic myeloid leukemia10024324NL-OMON49458Pfizer, Inc.66